Multiple clinical trials targeting inflammatory mediators including IL-1, IL-6, TNF-α, GM-CSF, M-CSF, IFN-γ, JAK1/JAK3, CCR2, CCR5, and complement C3/C5 are underway to treat COVID-19 patients [summarized in reference (Merad and Martin, 2020)]. This evidence concerns the gene IL6 and COVID-19.